1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 18th March 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Mapping microglia and astrocyte activation in vivo using diffusion MRI, 2022, Garcia-Hernandez et al

Discussion in 'Other health news and research' started by SNT Gatchaman, May 30, 2022.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    Mapping microglia and astrocyte activation in vivo using diffusion MRI
    Raquel Garcia-Hernandez, Antonio Cerdán Cerdá, Alejandro Trouve Carpena, Mark Drakesmith, Kristin Koller, Derek K Jones, Santiago Canals, Silvia De Santis

    While glia are increasingly implicated in the pathophysiology of psychiatric and neurodegenerative disorders, available methods for imaging these cells in vivo involve either invasive procedures or positron emission tomography radiotracers, which afford low resolution and specificity.

    Here, we present a noninvasive diffusion-weighted magnetic resonance imaging (MRI) method to image changes in glia morphology. Using rat models of neuroinflammation, degeneration, and demyelination, we demonstrate that diffusion-weighted MRI carries a fingerprint of microglia and astrocyte activation and that specific signatures from each population can be quantified noninvasively.

    The method is sensitive to changes in glia morphology and proliferation, providing a quantitative account of neuroinflammation, regardless of the existence of a concomitant neuronal loss or demyelinating injury. We prove the translational value of the approach showing significant associations between MRI and histological microglia markers in humans. This framework holds the potential to transform basic and clinical research by clarifying the role of inflammation in health and disease.

    Link | PDF | Supplementary Materials
     
    Last edited: May 30, 2022
    livinglighter, Arvo, shak8 and 17 others like this.
  2. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    Induced neuroinflammation in rats vs healthy controls. "Phase 1" style evaluation in healthy humans.


     
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,529
    Location:
    Aotearoa New Zealand
    That sounds exciting @SNT Gatchaman. Are you excited?

    Spanish and UK researchers.
     
  4. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    Yes. We're all crying out for a biomarker and the expectation has been that it would be found in the form of an immune cell/mediator signal or something similar, obtainable from blood. I have found it ironic that my own specialty has not helped me in the slightest (I only ever had a chest radiograph through this). However, I had always hoped that neuroimaging might advance to help us all. We could never biopsy the brain, but perhaps this technique will be a step away from "all tests normal". Also, sounds potentially useful for many conditions.

    Tantalising to think this could end up being an equivalent to MS patients having their demyelinating plaques shown on MRI (or CT), to facilitate diagnosis and support disease surveillance.

    I need to read the paper through in depth, and would like to see some pretty pictures in (affected) humans soon. This sort of technique would offer potential to see more directly into a hidden world that has only previously been inferred. Much work has been done to suggest that neuroinflammation, persistent glial hyperactivation etc are a big part of the symptomatology. And of course this would underscore the validity of the E in the original ME, which for many years has been so widely disputed by naysayers that this can not possibly be encephalitis/encephalomyelitis.

    One of the aspects to note is the suggestion that this technique could relatively easily translate onto the fleet of in-service clinical MRIs, which are generally 3T strength. Previously, it might have been thought that research magnets at 7T or beyond would be needed for resolution (eg vanElzakker has a study on brainstem at high-field strength). They won't even approach mainstream for a decade or two.

    Some in long Covid groups are commenting on the similarity to their past experiences post concussion. Perhaps that reflects commonalities neuroinflammation +/- BBB failure, although not post-traumatic in our situation.
     
  5. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    Unfortunately it wouldn't be a question of changing some presets on our current machines and pushing the big blue start button. The manufacturers would need to translate, evaluate for accuracy and safety and then produce an add-on package. Even if it was ready and validated in humans from a research perspective it would be 2-3 years minimum, as medical device certification is molasses for mostly very good reasons. Also it would be expensive as an add-on, so won't be coming to our hospital magnets as a diagnostic soon, without a champion pushing for it. I can't see neurologists thinking of FND/ME patients first up in this scenario!

    I guess if there is merit for diagnosing large numbers of LC patients - then who knows? - perhaps it could be warp-speeded into deployment. But for now I think the promise is with our researchers who might be able to power up their neuroinflammation studies. The targeted tracer PET imaging that we currently have suffers from very poor spatial resolution.

    ETA: DWI is pretty low spatial res itself but can map onto structural sequences. All of that is without the radiation penalty of a PET tracer and the accompanying CT, so much easier to gain ethics for human subjects.
     
    Last edited: May 30, 2022
  6. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,529
    Location:
    Aotearoa New Zealand
    There's the NZ Brain Institute in Christchurch, New Zealand. A study there might be relatively cheap.
    https://www.nzbri.org
    There's an MS specialist who is an active researcher there, and the national MS Society is pretty well set up. Maybe govt funds can be obtained to add a Long Covid arm to a trial. Do you think it might be worth contacting these researchers to see if they'd be interested in collaborating in a trial? If they were, perhaps we could pull something together?
     
  7. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    I've had a read through now and I need to reverse some of my earlier off-the-cuff comment. I've added a link to the supplementary materials in the first post. As far as I can tell from their methods, you probably could acquire the data on any clinical machine right now — so that aspect is better than I thought earlier. This is at high res, but I'll check with one of my techs whether it's feasible with typical setups.

    Diffusion-weighted imaging is a basic MRI technique that looks at impairment to the free movement of water molecules (Brownian motion) to make inferences about anatomy and pathology. Eg in ischaemic necrosis (such as stroke), dying cells are swollen as their Na/K pumps fail and the increased intracellular water (which was moving freely in the extracellular space before) can't move around so much now. Once the cell walls' integrity is lost, that reverses and diffusion restriction becomes less, often seen 24-48 hours after stroke onset.

    The gold though is in the model they have developed, which allows them to separate out the cell compartments and pathological processes. This looks like it's a custom MATLAB model they've developed, which is able to discriminate neuroinflammation in the presence or absence of demyelination and neuronal loss. The animal studies leading to this model are quite elegant (if you're not the rat).

    The multi-compartment model they've developed then relates back to postmortem studies that define glial geography as it varies through the human brain. The result is a model of "spheres" and "sticks", such that small sphere size, stick fraction and stick dispersion correlate with microglial morphology. This is quite mind-blowing as an advance.

    As they comment, traditionally we often report regions of non-specific "damage". We'd like to say more but often are only proposing possibilities. The authors appear to be offering the ability to define which cell compartments are involved in activation — microglia or astrocyte — regardless of the associated damage in terms of demyelination or neuronal loss. This would really help in defining pathology.

    I expect the model would remain proprietary (pretty valuable IP I'd imagine). Not sure if the general concept could be re-engineered past the gaps in their description. I'll run it past a few people that understand these things better than me. It's been 25 years since I studied MRI physics and I only do routine brain MRI.

    Give me a little time to get some feedback, but at this stage I'm not sure anyone else can progress with what we have available. So we're probably behind where we would need to be to do a trial in ME or MS, Parkinson's etc.
     
  8. Creekside

    Creekside Senior Member (Voting Rights)

    Messages:
    933
    It certainly does sound like a major boost to 'seeing' what's going on in brains. Even with its limitations, some 'before, during and after PEM' scans might reveal something useful.
     
    Jacob Richter, Ash, Simon M and 4 others like this.
  9. ME/CFS Skeptic

    ME/CFS Skeptic Senior Member (Voting Rights)

    Messages:
    3,494
    Location:
    Belgium
    An article about this paper: Magnetic resonance imaging shows brain inflammation in vivo for the first time (medicalxpress.com)

    It sounds interesting. Here's a relevant paragraph:

    "An innovative strategy developed by the researchers has made possible this important breakthrough, which is published today in the journal Science Advances and which may be crucial to change the course of the study and treatment of neurodegenerative diseases.

    The research demonstrates that diffusion-weighted MRI can noninvasively and differentially detect the activation of microglia and astrocytes, two types of brain cells that are at the basis of neuroinflammation and its progression.

    Degenerative brain diseases such as Alzheimer's and other dementias, Parkinson's or multiple sclerosis are a pressing and difficult problem to address. Sustained activation of two types of brain cells, microglia and astrocytes, leads to chronic inflammation in the brain that is one of the causes of neurodegeneration and contributes to its progression.

    However, there is a lack of non-invasive approaches capable of specifically characterizing brain inflammation in vivo. The current gold standard is positron emission tomography (PET), but it is difficult to generalize and is associated with exposure to ionizing radiation, so its use is limited in vulnerable populations and in longitudinal studies, which require the use of PET repeatedly over a period of years, as is the case in neurodegenerative diseases.

    Another drawback of PET is its low spatial resolution, which makes it unsuitable for imaging small structures, with the added drawback that inflammation-specific radiotracers are expressed in multiple cell types (microglia, astrocytes and endothelium), making it impossible to differentiate between them."

    In the face of these drawbacks, diffusion-weighted MRI has the unique ability to image brain microstructure in vivo noninvasively and with high resolution by capturing the random movement of water molecules in the brain parenchyma to generate contrast in MRI images.​
     
    Arvo, Amw66, Jacob Richter and 7 others like this.
  10. FMMM1

    FMMM1 Senior Member (Voting Rights)

    Messages:
    2,595
    Apologies for my standard reply, but if a brain abnormality were demonstrated in people with ME/CFS, using MRI, then that may provide a way to select a "purer" population for studies like GWAS (like DecodeME) - or indeed studies generally.
    I recall that Jarred Younger was researching inflammation using scans - like MRI - interesting to have his take on this publication.

    EDIT - This could be a way to "unite" ME/CFS, Lyme, long covid----

    @SNT Gatchaman - apologies - are you a medical doctor?
     
    Last edited: Oct 8, 2023
  11. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,256
    Location:
    Aotearoa New Zealand
    Yes. But it feels more like being a medical student again!
     
    RedFox, livinglighter, FMMM1 and 2 others like this.

Share This Page